Top

Published in:

01-12-2011 | Erectile Dysfunction (Tom Lue, Section Editor)

Emerging and Novel Therapeutic Approaches in the Treatment of Male Erectile Dysfunction

Authors: Eric Chung, Gerald B. Brock

Published in: Current Urology Reports | Issue 6/2011

Abstract

Over the past few decades, a dramatic increase in our understanding of the pathophysiology of penile erection has occurred. The advent of phosphodiesterase type 5 inhibitors has revolutionized the treatment of erectile dysfunction (ED), while the introduction of modern penile prosthesis has almost completely replaced the need for vascular surgery. Despite the efficacy of current therapeutic options for ED, they are not without limitations and remain insufficient to address the growing patient population and various underlying medical conditions. Newer and novel ED therapies aspire to treat underlying microvascular abnormalities, prevent cavernosal fibrosis, promote endothelial revascularization, modulate neurohormonal pathways, and regenerate new penile tissue.

Johannes CB, Araujo AB, Feldman HA, Derby CA, Kleinman KP, McKinlay JB. Incidence of erectile dysfunction in men 40–69 years old: longitudinal results from the Massachusetts Male Aging Study. J Urol. 2000;163:460–3.PubMedCrossRef

Lewis RW, Fugl-Meyer KS, Bosch R, et al. Epidemiology/risk factors of sexual dysfunction. J Sex Med. 2004;1:35–9.PubMedCrossRef

Gittelman M, McMahon CG, Rodrigues-Rivera JA, Beneke M, Ulbrich E, Ewald S. The POTENT II randomised trial: efficacy and safety of an orodispersible vardenafil formulation for the treatment of erectile dysfunction. Int J Clin Pract. 2010;64:594–603.PubMedCrossRef

Corona C, Maggi M. The role of testosterone in erectile dysfunction. Nat Rev Urol. 2010;7:46–56.PubMedCrossRef

Morelli A, Filippi S, Mancina R, et al. Androgens regulate phosphodiesterase type 5 expression and functional activity in corpora cavernosa. Endocrinology. 2004;145:2253–63.PubMedCrossRef

Palit V, Eardley I. An update of new oral PDE5 inhibitors for the treatment of erectile dysfunction. Nat Rev Urol. 2010;7:603–9.PubMedCrossRef

Somlyo AP, Somlyo AV. Signal transduction by G-proteins, rho-kinase and protein phosphatise to smooth muscle and non-muscle myosin II. J Physiol. 2000;15:177–85.CrossRef

Chitaley K, Webb RC, Mills TM. Rho-kinase as a potential target for the treatment of erectile dysfunction. Drugs News Prospect. 2001;14:601–6.

Jin L, Burnett AL. RhoA/Rho-kinase in erectile tissue: Mechanisms of disease and therapeutic insights. Clin Sci. 2006;110:153–65.PubMedCrossRef

10.

Vignozzi L, Morelli A, Filippi S, et al. Testosterone regulates RhoA/Rho-kinase signaling in two distinct animal models of chemical diabetes. J Sex Med. 2007;4:620–30. discussion 631–32.PubMedCrossRef

11.

Park K, Kim SW, Rhu KS, et al. Chronic administration of an oral Rho-kinase inhibitor prevents the development of vasculogenic erectile dysfunction in a rat model. J Sex Med. 2006;3:996–1003.PubMedCrossRef

12.

Demir O, Murat N, Aslan G, et al. Effect of doxazosin with and without rho-kinase inhibitor on human corpus cavernosum smooth muscle in the presence of bladder outlet obstruction. J Urol. 2006;175:2345–9.PubMedCrossRef

13.

Martin WJ, MacIntyre DE. Melanocortin receptors and erectile function. Eur Urol. 2004;45:706–13.PubMedCrossRef

14.

Wessells H, Levine N, Hardley ME, Dorr R, Hruby V. Melanocortin receptor agonists, penile erection, and sexual motivation: Human studies with Melanotan II. Int J Impot Res. 2000;12(s4):S74–9.PubMedCrossRef

15.

Diamond LE, Earle DC, Garcia WD, Spana C. Co-administration of low doses of intranasal PT-141, a melanocortin receptor agonist, and sildenafil to men with erectile dysfunction results in an enhanced erectile response. Urology. 2005;65(4):755–9.PubMedCrossRef

16.

Steidle CP et al. Phase IIB study of bremelanotide in the treatment of ED in diabetic males (abstract 1177). J Urol. 2007;177(s4):388.

17.

Lue TF. Surgery for crural venous leakage. Urology. 1999;54:739–41.PubMedCrossRef

18.

Sohn M. Current status of penile revascularization for the treatment of male erectile dysfunction. J Androl. 1994;15(3):183–6.PubMed

19.

Babaei AR, Safarinejad MR, Kolahi AA. Penile revascularization for erectile dysfunction: A systematic review and meta-analysis of effectiveness and complications. Urol J. 2009;6(1):1–7.PubMed

20.

• Rogers JH, Karimi H, Kao J, Link D et al. Internal pudendal artery stenoses and erectile dysfunction: Correlation with angiographic coronary artery disease. Cath Cardiovasc Interv 2010;76(6):882–7. This study represents the first angiographic report of coronary artery disease correlated with internal pudendal artery disease in patients with erectile dysfunction.

21.

Gibbons GH, Dzau VJ. The emerging concept of vascular remodelling. N Eng J Med. 1994;330:1431–8.CrossRef

22.

Ferrara N, Gerber HP, LeCouter J. The biology of VEGF and its receptors. Nat Med. 2003;9:669–76.PubMedCrossRef

23.

Shirai M, Yamanaka M, Shiina H, et al. vascular endothelial growth factor restores erectile function through modulation of the insulin-like growth factor system and sex hormone receptors in diabetic rat. Biochem Biophys Res Commun. 2006;341(3):755–62.PubMedCrossRef

24.

Hood JD, Meininger CJ, Ziche M, Granger HJ. VEGF upregulates eNOS message, protein, and NO production in human endothelial cells. Am J Physiol. 1998;274:H1054–8.PubMed

25.

Larcer F, Murillas R, Bolontrade M, Conti CJ, Jorcano JL. VEGF/VPP overexpression in skin of transgenic mice induces angiogenesis, vascular hyperpermeability and accelerated tumor development. Oncogene. 1998;17:303–11.CrossRef

26.

Dai Q, Silverstein AD, Davies MG, et al. Systemic basic fibroblast growth factor induces favourable histological changes in the corpus cavernosum of hypercholesterolemic rabbit. J Urol. 2003;170:664–8.PubMedCrossRef

27.

Ryu JK, Shin HY, Song SU, et al. Downregulation of angiogenic factors and their downstream target molecules affects the deterioration of erectile function in a rat model of hypercholesterolemia. Urology. 2006;67:1329–34.PubMedCrossRef

28.

•• Lysiak JJ, Kavoussi PK, Ellati RT, Steers WD, Annex BH. Angiogenesis therapy for the treatment of erectile dysfunction. J Sex Med 2010;7(7):2554–63. This article summarizes the results from all angiogenic therapies for the treatment of erectile dysfunction.

29.

Bakircioglu ME, Lin CS, Fan P, et al. The effect of adeno-associated virus mediated brain derived neurotrophic factor in an animal model of neurogenic impotence. J Urol. 2001;165:2103–9.PubMedCrossRef

30.

Kato R, Wolfe D, Coyle CH, et al. Herpes simplex virus vector-mediated delivery of glial cell line-derived neurotrophic factor rescues erectile dysfunction following cavernous nerve injury. Gene Ther. 2007;14:1344–52.PubMed

31.

Podlasek CA, Meroz CL, Tang Y, et al. Regulation of cavernous nerve-injury apoptosis by sonic hedgehog. Biol Reprod. 2007;76(1):19–28.PubMedCrossRef

32.

Bond CW, Angeloni NL, Arrington DA, et al. Peptide amphiphile nanofiber delivery of sonic hedgehog protein to reduce smooth muscle apoptosis in the penis after cavernous nerve resection. J Sex Med. 2011;8(1):78–89.PubMedCrossRef

33.

• Sezen SF, Lagoda G, Burnett AL. Role of immunophillins in recovery of erectile function after cavernous nerve injury. J Sex Med. 2009;6(3):340–6. This article reviews the current understanding on immunophilin proteins and the neurotrophic effects in erectile recovery following CNI.

34.

Allaf ME, Hoke A, Burnett AL. Erythropoietin promotes the recovery of erectile function following cavernous nerve injury. J Urol. 2005;174:2060–4.PubMedCrossRef

35.

Burnett AL, Allaf ME, Bivalacqua TJ. Erythropoietin promotes erection recovery after nerve-sparing radical retropubic prostatectomy: A retrospective analysis. J Sex Med. 2008;5:2392–8.PubMedCrossRef

36.

Melman A, Bar-Chama N, McCullough A, et al. hMaxi-K gene transfer in males with erectile dysfunction: Results of the first human trial. Hum Gene Ther. 2006;17:1165–76.PubMedCrossRef

37.

Christ GJ, Melman A. The application of gene therapy to the treatment of erectile dysfunction. Int J Impot Res. 1998;10:111–2.PubMedCrossRef

38.

Melman A, Christ GJ. Integrative erectile biology. The effects of age and disease on gap junctions and ion channels and their potential value to the treatment of erectile dysfunction. Urol Clin North Am. 2001;28:217–31.PubMedCrossRef

39.

Bivalacqua TJ, Champion HC, Mehta YS, et al. Adenoviral gene transfer of endothelial nitric oxide synthase (eNOS) to the penis improves age-related erectile dysfunction in the rat. Int J Impot Res. 2000;12 suppl 3:S8–17.PubMedCrossRef

40.

Bivalacqua TJ, Usta MF, Champion HC, et al. Gene transfer of endothelial nitric oxide synthase partially restores nitric oxide synthesis and erectile function in streptozocin diabetic rats. J Urol. 2003;169:1911–17.PubMedCrossRef

41.

Bivalacqua TJ, Usta MF, Champion HC, et al. Effect of combination endothelial nitric oxide synthase gene therapy and sildenafil on erectile function in diabetic rats. Int J Impot Res. 2004;16:21–9.PubMedCrossRef

42.

Bivalacqua TJ, Deng W, Kendirci M, et al. Mesenchymal stem cells alone or ex vivo gene modified with endothelial nitric oxide synthase reverses age-associated erectile dysfunction. Am J Physiol heart Circ Physiol. 2007;292:H1278–90.PubMedCrossRef

43.

Magee TR, Ferrini M, Garban HJ, et al. Gene therapy of erectile dysfunction in the rat with penile neuronal nitric oxide synthase. Biol Reprod. 2002;67:20–8.PubMedCrossRef

44.

Garban H et al. Cloning of rat and human inducible penile nitric oxide synthase. Application for gene therapy of erectile dysfunction. Biol Reprod. 1997;56:954–63.PubMedCrossRef

45.

Chancellor MB, Tirney S, Mattes CE, et al. Nitric oxide synthase gene transfer for erectile dysfunction in a rat model. BJU Int. 2003;91:691–6.PubMedCrossRef

46.

Magee TR, Kovanecz I, Davila HH, et al. Antisense and short hairpin RNA (shRNA) constructs targeting PIN (Protein Inhibitor of NOS) ameliorate aging-related erectile dysfunction in rat. J Sex Med. 2007;4:633–43.PubMedCrossRef

47.

Bivalacqua TJ, Burnett AL, Hellstrom WJ, Champion HC. Overexpression of arginase in the aged mouse penis impairs erectile function and decreases eNOS activity:influence of in vivo gene therapy of anti-arginase. Am J Physiol Heart Circ Physiol. 2007;292:H1320–51.

48.

Bivalacqua TJ, Kendirci M, Champion HC, et al. Dysregulation of cGMP-dependent protein kinase 1 (PKG-1) impairs erectile function in diabetic rats: influence of in vivo gene therapy of PKG 1 alpha. BJU Int. 2007;99:1488–94.PubMedCrossRef

49.

Bivalacqua TJ et al. Superoxide anion production in the rat penis impairs erectile function in diabetes: influence of in vivo extracellular superoxide dismutase gene therapy. J Sex med. 2005;2:187–97.PubMedCrossRef

50.

Markus A, Patel TD, Snider WD. Neurotrophic factors and axonal growths. Curr Opin Neurobiol. 2002;12:523–31.PubMedCrossRef

51.

Kato R, Wolfe D, Coyle CH, et al. Herpes simplex virus vector-mediated delivery of neurturin rescues erectile dysfunction of cavernous nerve injury. Gene Ther. 2009;16:23–33.CrossRef

52.

Lin G, Chen KC, Hsieh PS, et al. Neurotrophic effects of vascular and endothelial growth factor and neurotrophins on cultured major pelvic ganglia. BJU Int. 2003;952:631–5.CrossRef

53.

Bennett NE, Kim JH, Wolfe DP, et al. Improvement in erectile dysfunction after neurotrophic actor gene therapy in diabetic rats. J Urol. 2005;173:1820–4.PubMedCrossRef

54.

Gholami SS, Rogers R, Chang J, et al. The effect of vascular endothelial growth factor and adeno-associated virus mediated brain derived neurotrophic factor on neurogenic and vasculogenic erectile dysfunction induced by hyperlipidemia. J Urol. 2003;169:1577–81.PubMedCrossRef

55.

Rogers RS, Graziottin TM, Lin CS, et al. Intracavernosal vascular endothelial growth factor (VEGF) injection and adeno-associated virus-mediated VEGF gene therapy prevent and reverse venogenic erectile dysfunction in rats. Int J Impot Res. 2003;15:26–37.PubMedCrossRef

56.

Yamanaka M, Shirai M, Shiina H, et al. Vascular endothelial growth factor restores erectile function through inhibition of apoptosis in diabetic rat penile crura. J Urol. 2005;173:318–23.PubMedCrossRef

57.

Ryu JK, Cho CH, Skin HY, et al. Combined angiopoietin-1 and vascular endothelial growth factor gene transfer restores cavernous angiogenesis and erectile function in a rat model of hypercholesterolemia. Mol Ther. 2006;13:705–15.PubMedCrossRef

58.

Abdel Aziz MT, Mostafa T, Atta H, et al. Effect of HO-1 cDNA-liposome complex transfer on erectile signalling of aged rats. Andrologia. 2009;41:176–83.PubMedCrossRef

59.

Bivalacqua TJ, Usta MF, Kendirci M, et al. Superoxide anion production in the rat penis impairs erectile function in diabetes: influence of in vivo extracellular superoxide dismutase gene therapy. J Sex Med. 2005;2(2):187–97. discussion 197–8.PubMedCrossRef

60.

Anderson KE, Wagner G. Physiology of penile erection. Physiol Rev. 1995;75:191–236.

61.

Spektor M, Rodriguez R, Rosenbaum RS, et al. Potassium channels and human corporeal smooth muscle cell tone: further evidence of the physiological relevance of the Maxi-K channel subtype to the regulation of human corporeal smooth muscle tone in vitro. J Urol. 2002;167:2628–35.PubMedCrossRef

62.

Melman A, Zhao W, Davies KP, Bakal R, Christ GJ. The successful long-term treatment of age related erectile dysfunction with hSlo cDNA in rats in vivo. J Urol. 2003;170:285–90.PubMedCrossRef

63.

Christ GJ, Day N, Santizo C, et al. Intracorporal injection of hSlo cDNA restores erectile capacity in STZ-diabetic F-344 rats in vivo. Am J Physiol Heart Circ Physiol. 2004;287:H1544–53.PubMedCrossRef

64.

Christ GJ, Rehman J, Day N, et al. Intracorporal injection of hSlo cDNA in rats produces physiologically relevant alterations in penile function. Am J Physiol. 1998;275:H600–8.PubMed

65.

Melman A, Biggs G, Davies K, et al. Gene transfer with a vector expressing Maxi-K from a smooth muscle-specific promoter restores erectile function in the aging rat. Gene Ther. 2008;15:364–70.PubMedCrossRef

66.

• Christ GJ, Andersson KE, Williams K et al. Smooth-muscle-specific gene transfer with the human Maxi-K channel improves erectile function and enhances sexual behaviour in atherosclerotic cynomolgus monkeys. Eur Urol 2009;52:1055–66. This study shows dramatic changes in erectile function and sexual behavior following intracorporal Maxi-K gene transfer in primate species.

67.

Melman A, Rojas L, Christ G. Gene transfer for erectile dysfunction: will this novel therapy be accepted by urologist? Curr Opin Urol. 2009;19:595–600.PubMedCrossRef

68.

Venkateswarlu K, Giraldi A, Zhao W, et al. Potassium channels and human corporeal smooth muscle tone: diabetes and relaxation of human corpus cavernosum smooth muscle by adenosine triphosphate sensitive potassium channel openers. J Urol. 2002;168:355–61.PubMedCrossRef

69.

So I, Chae MR, Lee SW. Gene transfer of the K(ATP) channel restores age-related erectile dysfunction in rats. BJU Int. 2007;100:1154–60.PubMed

70.

Stief CG, Benard F, Bosch R, et al. Calcitonin gene-related peptide: possibly neurotransmitter contributes to penile erection in monkeys. Urology. 1993;41:397–401.PubMedCrossRef

71.

Bivalacqua TJ, Champion HC, Abdel-Mageed AB, Kadowitz PJ, Hellstrom WJ. Gene transfer of prepro-calcitonin gene-related peptide restores erectile function in the aged rat. Biol Reprod. 2001;65:1371–7.PubMedCrossRef

72.

Shen ZJ, Wang H, Lu YL, et al. Gene transfer of vasoactive intestinal polypeptide into the penis improves erectile response in the diabetic rat. BJU Int. 2005;95(6):890–4.PubMedCrossRef

73.

Wessells H, Williams SK. Endothelial cell transplantation into the corpus cavernosum: Moving towards cell-based gene therapy. J Urol. 1999;162:2162–4.PubMedCrossRef

74.

Bochinski D, Lin GT, Nunes L, et al. The effect of neural embryonic stem cell therapy in a rat model of cavernosal nerve injury. BJU Int. 2004;94:904–9.PubMedCrossRef

75.

Song YS, Lee HJ, Park IH, et al. Human neural crest stem cells transplanted in rat penile corpus cavernosum to repair erectile dysfunction. BJU Int. 2008;102:220–4. discussion 224.PubMedCrossRef

76.

Song YS, Lee HJ, Park IH, et al. Potential differentiation of human mesenchymal stem cell transplanted in rat corpus cavernosum toward endothelial or smooth muscle cells. Int J Impot Res. 2007;19:378–85.PubMedCrossRef

77.

Nolazco G, Kovanecz I, Vernet D, et al. Effect of muscle-derived stem cells on the restoration of corpora cavernosa smooth muscle and erectile function in the aged rat. BJU Int. 2008;101:1156–64.PubMedCrossRef

78.

• Kendirci M, Trost L, Bakondi B et al. Transplantation of nonhematopoietic adult bone marrow stem/progenitor cells isolated by p75 nerve growth factor receptor into the penis rescues erectile function in a rat model of cavernous nerve injury. J Urol. 2010;184(4):1560–6. This article highlights the role of p75-derived multipotent stromal cells harvested from adult bone marrow in recovery of erectile function following bilateral cavernous nerve crush injury.

79.

Huang YC, Ning H, Shindel AW, et al. The effect of intracavernous injection of adipose tissue-derived stem cells on hyperlipidemia-associated erectile dysfunction in a rat model. J Sex Med. 2011;7(4 Pt 1):1391–400.

80.

• Albersen M, Fandel TM, Lin G et al. Injections of adipose tissue-derived stem cells and stem cell lysate improve recovery of erectile function in a rat model of cavernous nerve injury. J Sex Med 2010;7(10):3331–40. This article reports significant recovery in erectile function following ADSC and lysate treatments and that the underlying mechanism of recovery involved neuron preservation and cytoprotection by inhibition of cellular apoptosis.

81.

•• Harraz A, Shindel AW, Lue TF. Emerging gene and stem cell therapies for the treatment of erectile dysfunction. Nat Rev Urol. 2010:7:143–52. This article provides a succinct summary on the pertinent studies relating to gene and stem-cell therapies.

82.

Wood D, Southgate J. Current status of tissue engineering in urology. Curr Opin Urol. 2008;18:564–9.PubMedCrossRef

83.

Atala A. Tissue engineering applications for erectile dysfunction. Int J Impot Res. 1999;11(s1):s41.PubMedCrossRef

84.

• Chen KL, Eberli D, Yoo JJ, Atala A. Bioengineered corporal tissue for structural and functional restoration of the penis. Proc Natl Acad Sci USA. 2010;107(8):3346–50. This study shows that neo-corpora engineered from cavernosal collagen matrices could replaced the entire pendular penile corporal bodies in a rabbit model and also demonstrated structural and functional parameters similar to native tissue.

85.

Falke G, Yoo JJ, Machado MG, Moreland R, Atala A. Formation of corporal tissue architecture in vivo using human cavernosal muscle and endothelial cells seeded on collagen matrices. Tissue Eng. 2003;9:871–79.PubMedCrossRef

86.

Eberli D, Susaeta R, Yoo JJ, Atala A. A method to improve cellular content for corporal tissue engineering. Tissue Eng Part A. 2008;14(10):1581–9.PubMedCrossRef

87.

Connolly SS, Yoo JJ, Abouheba M, et al. Cavernous nerve regeneration using acellular nerve grafts. World J Urol. 2008;26(4):333–9.PubMedCrossRef

88.

Nurzynska D, Di Meglio F, Castaldo C, et al. Shock wave activate in vitro cultured progenitors and precursors of cardiac cell lineages from the human heart. Ultrasound Med Biol. 2008;34:334–42.PubMedCrossRef

89.

Kikuchi Y, Ito K, Ito Y, et al. Double-blind and placebo-controlled study of the effectiveness and safety of extracorporal cardiac shock wave therapy for severe angina pectoris. Circ J. 2010;74:589–91.PubMedCrossRef

90.

Wang CJ, Kuo YR, Wu RW, et al. Extracorporeal shockwave treatment for chronic diabetic foot ulcers. J Surg Res. 2009;152:96–103.PubMedCrossRef

91.

Gotte G, Amelio E, Russo S, et al. Short-time non-enzymatic nitric oxide synthesis from L-arginine and hydrogen peroxide induced by shock waves treatment. FEBS Lett. 2002;520:153–5.PubMedCrossRef

92.

Caspari GH, Erbel R. Revascularization with extracorporeal shock wave therapy: first clinical results. Circulation. 1999;100:84–9.

93.

Ciampa AR. Carcereri de Pratti A, Amelio E et al. Nitric oxide mediates anti-inflammatory action of extracorporeal shock waves. FEBS Lett. 2005;579:6839–45.PubMedCrossRef

94.

• Vardi Y, Appel B, Jacob G et al. Can low-intensity extracorporeal shockwave therapy improve erectile function? A 6-month follow-up pilot study in patients with organic erectile dysfunction. Eur Urol 2010;58(2):243–8. This study provides proof-of-concept that low-intensity extracorporeal shock wave therapy is effective and tolerable for the treatment of vasculogenic ED. Furthermore, it improves endothelial function and has the potential to play an important role in penile rehabilitation without pharmacotherapy.

95.

Müller A, Akin-Olugbade Y, Deveci S, et al. The impact of shock wave therapy at varied energy and dose levels on functional and structural changes in erectile tissue. Eur Urol. 2008;53:635–43.PubMedCrossRef

Title: Emerging and Novel Therapeutic Approaches in the Treatment of Male Erectile Dysfunction
Authors: Eric Chung
Gerald B. Brock
Publication date: 01-12-2011
Publisher: Current Science Inc.
Published in: Current Urology Reports / Issue 6/2011
Print ISSN: 1527-2737
Electronic ISSN: 1534-6285
DOI: https://doi.org/10.1007/s11934-011-0216-y

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Emerging and Novel Therapeutic Approaches in the Treatment of Male Erectile Dysfunction

Abstract

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 6/2011

Bladder Dysfunction in Patients with Diabetes

Penile Fracture and Penile Reconstruction

Combination Surgery for Erectile Dysfunction and Male Incontinence

Updates in the Management of the Overactive Bladder in Patients with Myelomeningocele

The Scientific Rationale for Using Biomaterials in Stress Urinary Incontinence and Pelvic Organ Prolapse

Neurogenic Detrusor Overactivity in Patients With Spinal Cord Injury: Evaluation and Management